Efficacy

Efficacy of Cibinqo (abrocitinib) for Atopic Dermatitis

Cibinqo (abrocitinib) is a Janus kinase (JAK) inhibitor that has been approved for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Clinical trials have demonstrated that abrocitinib significantly improves the signs and symptoms of atopic dermatitis, including itch, skin inflammation, and the overall extent of the disease. Patients treated with abrocitinib have shown a marked reduction in disease severity as measured by objective signs and patient-reported outcomes.

In pivotal phase 3 trials, a significant proportion of patients achieved at least a 75% reduction in the Eczema Area and Severity Index (EASI-75) from baseline, which is a common measure of disease severity. Moreover, abrocitinib has been associated with a rapid onset of action, with some patients experiencing relief from itch as early as within two days of starting the treatment. The efficacy of abrocitinib was sustained over time, with long-term studies supporting its continued benefit in maintaining disease control with an acceptable safety profile.

Efficacy of Opzelura (ruxolitinib) for Atopic Dermatitis

Opzelura (ruxolitinib) is another JAK inhibitor, but it is formulated as a topical cream for the treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. It is the first topical JAK inhibitor approved by the FDA for this condition. Clinical studies have shown that Opzelura effectively reduces the inflammation and pruritus associated with atopic dermatitis. Patients using Opzelura have reported improvements in itch relief within 12 hours after the first application, which can significantly enhance the quality of life for individuals with atopic dermatitis.

In clinical trials, Opzelura demonstrated a significant improvement in the Investigator's Global Assessment (IGA) score, which measures the global severity of atopic dermatitis. A meaningful proportion of patients achieved IGA scores of 0 or 1, indicating clear or almost clear skin, with at least a 2-point improvement from baseline. The efficacy of Opzelura was consistent across various demographic and baseline disease characteristics, making it a versatile option for a broad range of patients with atopic dermatitis.